| Pharmaceutical Information |
| Drug Name |
Clobetasol |
| Drug ID |
BADD_D00489 |
| Description |
Clobetasol is under investigation for the treatment of Scleroderma. Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids. |
| Indications and Usage |
Not Available |
| Marketing Status |
approved; experimental; investigational |
| ATC Code |
D07AD01 |
| DrugBank ID |
DB11750
|
| KEGG ID |
D07715
|
| MeSH ID |
D002990
|
| PubChem ID |
5311051
|
| TTD Drug ID |
D0FL5V
|
| NDC Product Code |
Not Available |
| UNII |
ADN79D536H
|
| Synonyms |
Clobetasol | Clofenazon | Clobetasol Propionate | Clobetasol 17-Propionate | Clobetasol 17 Propionate | Clobex | Cormax | OLUX | Dermovate | Embeline | Embeline E | Temovate |
|
| Chemical Information |
| Molecular Formula |
C22H28ClFO4 |
| CAS Registry Number |
25122-41-2 |
| SMILES |
CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)F)C |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Infestation | 11.09.01.001; 23.11.01.002 | - | - | - | | Skin abrasion | 12.01.06.010; 23.03.11.018 | - | - | - | | Application site burn | 08.02.01.038; 12.07.01.038; 23.03.11.013 | - | - | - |
|
|
|
